Chargement en cours...
Epidemiological Challenges in Rare Bleeding Disorders: FVIII Inhibitor Incidence in Haemophilia A Patients—A Known Issue of Unknown Origin
There is a broad range of factor products approved in Germany for haemophilia A treatment. Since the introduction of recombinant coagulation factor VIII (FVIII) products in the 1990s, there has been substantial debate whether there is a difference in inhibitor incidence between single FVIII products...
Enregistré dans:
| Publié dans: | Int J Environ Res Public Health |
|---|---|
| Auteurs principaux: | , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
MDPI
2020
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7795862/ https://ncbi.nlm.nih.gov/pubmed/33396748 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijerph18010225 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|